Delays in radical prostatectomy due to the novel coronavirus disease (COVID-19) pandemic does not result in adverse pathology, upgrading, nodal metastasis, or use of postsurgery secondary treatments, according to a recent study.
Insulin-like growth factor 1 (IGF-1) to insulin-like growth factor–binding protein 2 (IGFBP-2) ratio ≤0.85 appears to be a useful biomarker in the diagnosis of pancreatic adenocarcinoma (PDAC), suggests a recent study.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Hypofractionated radiotherapy (HFRT) followed by HF tumour bed-boost may have similar tumour control without an increase in toxicities compared with conventional fractionated radiotherapy (CFRT) in patients with breast cancer after breast-conserving surgery (BCS), results of a multicentre, randomized, controlled trial have shown.
The use of granulocyte colony-stimulating factors (GCSFs) as primary prophylaxis (PP) reduces the incidence of febrile neutropenia (FN) and associated hospitalization among breast cancer patients receiving docetaxel-containing chemotherapy, with 4–5 days of PP offering similar efficacy and greater healthcare expenditure savings vs 7-day PP, results of a retrospective cohort study in Hong Kong have shown.
Pembrolizumab in combination with chemotherapy significantly improves overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) vs chemotherapy alone in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer, according to results of the phase III KEYNOTE-590 study presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Serum assessment of drug level may detect early nonadherence to adjuvant tamoxifen therapy and identify patients with early breast cancer at risk of poorer outcomes, new data from the CANTO study have shown.
A paclitaxel-carboplatin (PCb) regimen may be an alternative adjuvant chemotherapeutic strategy for women with operable triple-negative breast cancer (TNBC), given its greater benefit over a conventional regimen comprising cyclophosphamide, epirubicin, and fluorouracil, followed by docetaxel (CEF-T), the phase III PATTERN* trial has shown.
A blood serum microRNA biomarker signature for oropharyngeal squamous cell carcinoma was recently reported in the Journal of Translational Medicine.The researchers involved in its discovery are expanding on this finding to develop a blood test model that will help predict or diagnose head and neck cancers. [Available at https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02446-1 Accessed on 14 September 2020]
The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate 238 trial presented at ESMO 2020.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).